6322 related articles for article (PubMed ID: 3558118)
1. Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.
Mamber SW; Mitulski JD; Hamelehle KL; French JC; Hokanson GC; Shillis JL; Leopold WR; Von Hoff DD; Tunac JB
J Antibiot (Tokyo); 1987 Jan; 40(1):73-6. PubMed ID: 3558118
[TBL] [Abstract][Full Text] [Related]
2. Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.
Schurig JE; Bradner WT; Basler GA; Rose WC
Invest New Drugs; 1989 Jul; 7(2-3):173-8. PubMed ID: 2793369
[TBL] [Abstract][Full Text] [Related]
3. Biological effects of acetomycin. II. Inactivation by esterases in vitro.
Mamber SW; Mitulski JD; Borondy PE; Tunac JB
J Antibiot (Tokyo); 1987 Jan; 40(1):77-80. PubMed ID: 3558119
[TBL] [Abstract][Full Text] [Related]
4. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
Szmigielska-Kaplon A; Ciesielska E; Szmigiero L; Robak T
Eur J Haematol; 2002 Jun; 68(6):370-5. PubMed ID: 12225395
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A; Venditti JM; Geran R
Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis of (+/-)-acetomycin and design of esterase-resistant analogs.
Uenishi J; Kobayashi N; Komine S; Okadai T; Yonemitsu O; Sasaki T; Yamada Y
Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):517-23. PubMed ID: 10319430
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).
Roberts BJ; Hamelehle KL; Sebolt JS; Leopold WR
Cancer Chemother Pharmacol; 1986; 16(2):95-101. PubMed ID: 3081269
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
11. Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives.
Fry DW; Shillis JL; Leopold WR
Invest New Drugs; 1986; 4(1):3-10. PubMed ID: 3754542
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of spergualin, a novel antitumor antibiotic.
Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Oct; 39(10):1461-6. PubMed ID: 3781914
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
14. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.
Jackson RC; Fry DW; Boritzki TJ; Roberts BJ; Hook KE; Leopold WR
Adv Enzyme Regul; 1985; 23():193-215. PubMed ID: 3840949
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of bacteriohopane-32-ol against mouse leukemia L1210 and P388 cells in vitro.
Nagumo A; Takanashi K; Hojo H; Suzuki Y
Toxicol Lett; 1991 Nov; 58(3):309-13. PubMed ID: 1957326
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
Chiuten DF; Muggia FM; Johnson RK
Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
[No Abstract] [Full Text] [Related]
17. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
18. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
19. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic activity of didemnin congeners: nordidemnin and modified chain analogues.
Jouin P; Poncet J; Dufour MN; Aumelas A; Pantaloni A; Cros S; François G
J Med Chem; 1991 Feb; 34(2):486-91. PubMed ID: 1995869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
